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Background
Drug resistance developed by P. falciparum is a real threat
to malaria disease control and treatment. Recent reports
from the Thai-Cambodia and Thai-Myanmar borders
have described the artemisinin resistance developed by the
parasite. Therefore, there is a need to monitor emergence
of resistance parasites in order to limit their spread.
Materials and methods
Clinical isolates were collected from patients infected
with P. falciparum. The parasites were adapted in in
vitro culture and tested for 50% inhibitory concentration
(IC50) against pyrimethamine (Pyr), chloroquine (CQ),
mefloquine (MQ) and dihydroartemisinin (DHA) using
standard malaria SYBR Green I-based fluorescence
(MSF) assay. Mutations of genes associated with drug
resistance were also investigated.
Results and conclusions
All the tested clinical isolates were resistant to Pyr and
CQ, even though Pyr was not used in the area for a
long time, while CQ is still used to treat P. vivax infec-
tion. Only some of the isolates were resistant to MQ,
while all of them were sensitive to DHA using standard
drug sensitivity assay. Pyr- and CQ-resistant isolates
contained mutations at dihydrofolate reductase (Pfdhfr)
and chloroquine resistance transporter (Pfcrt) genes as
expected. The results confirm the existence of drug
resistance parasites and suggest the use of proper drugs
for malaria treatment in the field.
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